Last reviewed · How we verify
Fluorodopa F18 (fluorodopa (18F))
Fluorodopa F18, marketed by Feinstein, is a radiopharmaceutical used for PET imaging to evaluate suspected Parkinsonian syndromes, with a key composition patent expiring in 2028. Its primary strength lies in its mechanism of being taken up by dopamine-producing neurons, providing detailed imaging insights critical for diagnosis. The primary risk is competition from other same-class drugs, including iobenguane (123I), iobenguane (131I), fludeoxyglucose (18F), sodium fluoride F-18, and gallium (68Ga) edotreotide, which may limit market share and revenue growth.
At a glance
| Generic name | fluorodopa (18F) |
|---|---|
| Sponsor | Feinstein |
| Drug class | fluorodopa (18F) |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2019 |
Approved indications
- Evaluation of suspected Parkinsonian syndromes
Common side effects
- Pain
Drug interactions
- Aromatic L-amino acid decarboxylase (AADC) inhibitors (e.g., carbidopa, benserazide)
- Dopamine agonists, dopamine reuptake inhibitors, dopamine releasing agents (DRAs), peripheral catechol-O-methyltransferase (COMT) inhibitors, and monoamine oxidase (MAO) inhibitors
Key clinical trials
- Clinical Laboratory Evaluation of Chronic Autonomic Failure
- Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome (PHASE2)
- Diagnosis of Pheochromocytoma (PHASE1)
- Natural History of Familial Carcinoid Tumor
- [18F]F-DOPA Imaging in Patients With Autonomic Failure (PHASE1)
- An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors (PHASE2)
- 18F-DOPA II - PET Imaging Optimization (PHASE3)
- Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluorodopa F18 CI brief — competitive landscape report
- Fluorodopa F18 updates RSS · CI watch RSS
- Feinstein portfolio CI